Asset Details
Do you wish to reserve the book?
Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials
Do you wish to request the book?
Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials
2018
Overview
An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials in adults aged ≥50 and ≥70 years (ZOE-50 and ZOE-70, respectively).
Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke, and disseminated, ophthalmic, neurologic, and visceral diseases.
In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against HZ-related complications was 93.7% (95% confidence interval, 59.5–99.9%) in adults aged ≥50 years and 91.6% (43.3–99.8%) in adults ≥70 years. Five HZ-related hospitalizations, all in placebo recipients, and no HZ-related deaths were reported.
HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177; NCT01165229).
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Aged
/ Clinical Trials, Phase III as Topic
/ Disease
/ elderly
/ Female
/ Herpes Zoster - epidemiology
/ Herpes Zoster Vaccine - administration & dosage
/ Herpes Zoster Vaccine - adverse effects
/ Herpes Zoster Vaccine - immunology
/ Humans
/ Male
/ Neuralgia, Postherpetic - epidemiology
/ Neuralgia, Postherpetic - etiology
/ Pain
/ placebos
/ Stroke
/ Studies
/ Vaccination - adverse effects
/ Vaccines
/ Vaccines - administration & dosage
/ Vaccines, Subunit - administration & dosage
/ Vaccines, Subunit - adverse effects
